1
|
Meng Z, Liang H, Zhao J, Gao J, Liu C, Ma X, Liu J, Liang B, Jiao X, Cao J, Wang Y. HMOX1 upregulation promotes ferroptosis in diabetic atherosclerosis. Life Sci 2021; 284:119935. [PMID: 34508760 DOI: 10.1016/j.lfs.2021.119935] [Citation(s) in RCA: 71] [Impact Index Per Article: 23.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Revised: 08/27/2021] [Accepted: 08/30/2021] [Indexed: 12/26/2022]
Abstract
OBJECTIVE Atherosclerotic vascular disease remains the principal cause of death and disability among patients with type 2 diabetes. Unfortunately, the problem is not adequately resolved by therapeutic strategies with currently available drugs or approaches that solely focus on optimal glycemic control. To identify the key contributors and better understand the mechanism of diabetic atherosclerotic vascular disease, we aimed to elucidate the key genetic characteristics and pathological pathways in atherosclerotic vascular disease through nonbiased bioinformatics analysis and subsequent experimental demonstration and exploration in diabetic atherosclerotic vascular disease. METHODS AND RESULTS Sixty-eight upregulated and 23 downregulated genes were identified from the analysis of gene expression profiles (GSE30169 and GSE6584). A comprehensive bioinformatic assay further identified that ferroptosis, a new type of programmed cell death and HMOX1 (a gene that encodes heme oxygenase), were vital factors in atherosclerotic vascular disease. We further demonstrated that diabetes significantly increased ferroptosis and HMOX1 levels compared to normal controls. Importantly, the ferroptosis inhibitor ferrostatin-1 (Fer-1) effectively attenuated diabetic atherosclerosis, suggesting the causative role of ferroptosis in diabetic atherosclerosis development. At the cellular level, Fer-1 ameliorated high glucose high lipid-induced lipid peroxidation and downregulated ROS production. More importantly, HMOX1 knockdown attenuated Fe2+ overload, reduced iron content and ROS, and alleviated lipid peroxidation, which led to a reduction in ferroptosis in diabetic human endothelial cells. CONCLUSIONS We demonstrated that HMOX1 upregulation is responsible for the increased ferroptosis in diabetic atherosclerosis development, suggesting that HMOX1 may serve as a potential therapeutic or drug development target for diabetic atherosclerosis.
Collapse
Affiliation(s)
- Zhijun Meng
- Department of Physiology, Key Laboratory of Cellular Physiology, Shanxi Medical University, Taiyuan, Shanxi, China; Clinical Laboratory, Shanxi Provincial People's Hospital of Shanxi Medical University, Taiyuan, Shanxi, China; Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, United States of America
| | - Hongping Liang
- Clinical Laboratory, Shanxi Provincial People's Hospital of Shanxi Medical University, Taiyuan, Shanxi, China
| | - Jianli Zhao
- Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, United States of America
| | - Jia Gao
- Department of Physiology, Key Laboratory of Cellular Physiology, Shanxi Medical University, Taiyuan, Shanxi, China
| | - Caihong Liu
- Department of Physiology, Key Laboratory of Cellular Physiology, Shanxi Medical University, Taiyuan, Shanxi, China
| | - Xinliang Ma
- Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, United States of America
| | - Jing Liu
- Department of Physiology, Key Laboratory of Cellular Physiology, Shanxi Medical University, Taiyuan, Shanxi, China
| | - Bin Liang
- Department of Cardiology, The Second Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi, China
| | - Xiangying Jiao
- Department of Physiology, Key Laboratory of Cellular Physiology, Shanxi Medical University, Taiyuan, Shanxi, China
| | - Jimin Cao
- Department of Physiology, Key Laboratory of Cellular Physiology, Shanxi Medical University, Taiyuan, Shanxi, China.
| | - Yajing Wang
- Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, United States of America.
| |
Collapse
|
2
|
Liu J, Meng Z, Gan L, Guo R, Gao J, Liu C, Zhu D, Liu D, Zhang L, Zhang Z, Xie D, Jiao X, Lau WB, Lopez BL, Christopher TA, Ma X, Cao J, Wang Y. C1q/TNF-related protein 5 contributes to diabetic vascular endothelium dysfunction through promoting Nox-1 signaling. Redox Biol 2020; 34:101476. [PMID: 32122792 PMCID: PMC7327962 DOI: 10.1016/j.redox.2020.101476] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2019] [Revised: 02/19/2020] [Accepted: 02/21/2020] [Indexed: 12/19/2022] Open
Abstract
OBJECTIVE Dysregulated adipokine profiles contribute to the pathogenesis of diabetic cardiovascular complications. Endothelial cell (EC) dysfunction, a common pathological alteration in cardiovascular disorders, is exaggerated in diabetes. However, it is unclear whether and how dysregulated adipokines may contribute to diabetic EC dysfunction. METHODS AND RESULTS Serum C1q/TNF-Related Protein 5 (CTRP5) were determined in control/diabetes patients, and control/diabetic mice (high-fat diet, HFD). We observed for the first time that serum total CTRP5 was increased, high molecular weight (HMW) form was decreased, but the globular form (gCTRP5) was significantly increased in diabetic patients. These pathological alterations were reproduced in diabetic mice. To determine the pathological significance of increased gCTRP5 in diabetes, in vivo, ex vivo and in vitro experiments were performed. Diabetic atherosclerosis and EC dysfunction were significantly attenuated by the in vivo administration of CTRP5 neutralization antibody (CTRP5Ab). EC apoptosis was significantly increased in diabetic EC (isolated from HFD animal aorta) or high glucose high lipid (HGHL) cultured HUVECs. These pathological alterations were further potentiated by gCTRP5 and attenuated by CTRP5Ab. Pathway specific discovery-driven approach revealed that Nox1 expression was one of the signaling molecules commonly activated by HFD, HGHL, and gCTRP5. Treatment with CTRP5Ab reversed HFD-induced Nox1 upregulation. Finally, Nox1siRNA was used to determine the causative role of Nox1 in gCTRP5 induced EC apoptosis in diabetes. Results showed that gCTRP5 activated the mitochondrial apoptotic signal of EC in diabetes, which was blocked by the silencing Nox1 gene. CONCLUSION We demonstrated for the first time that gCTRP5 is a novel molecule contributing to diabetic vascular EC dysfunction through Nox1-mediated mitochondrial apoptosis, suggesting that interventions blocking gCTRP5 may protect diabetic EC function, ultimately attenuate diabetic cardiovascular complications.
Collapse
Affiliation(s)
- Jing Liu
- Department of Physiology, Shanxi Medical University, Shanxi, China; Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, USA
| | - Zhijun Meng
- Department of Physiology, Shanxi Medical University, Shanxi, China; Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, USA
| | - Lu Gan
- Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, USA
| | - Rui Guo
- Department of Physiology, Shanxi Medical University, Shanxi, China
| | - Jia Gao
- Department of Physiology, Shanxi Medical University, Shanxi, China
| | - Caihong Liu
- Department of Physiology, Shanxi Medical University, Shanxi, China
| | - Di Zhu
- Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, USA
| | - Demin Liu
- Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, USA
| | - Ling Zhang
- Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, USA
| | - Zhen Zhang
- Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, USA
| | - Dina Xie
- Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, USA
| | - Xiangying Jiao
- Department of Physiology, Shanxi Medical University, Shanxi, China
| | - Wayne Bond Lau
- Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, USA
| | - Bernard L Lopez
- Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, USA
| | | | - Xinliang Ma
- Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, USA
| | - Jimin Cao
- Department of Physiology, Shanxi Medical University, Shanxi, China.
| | - Yajing Wang
- Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, USA.
| |
Collapse
|
5
|
Gray SP, Di Marco E, Okabe J, Szyndralewiez C, Heitz F, Montezano AC, de Haan JB, Koulis C, El-Osta A, Andrews KL, Chin-Dusting JPF, Touyz RM, Wingler K, Cooper ME, Schmidt HHHW, Jandeleit-Dahm KA. NADPH Oxidase 1 Plays a Key Role in Diabetes Mellitus–Accelerated Atherosclerosis. Circulation 2013; 127:1888-902. [PMID: 23564668 DOI: 10.1161/circulationaha.112.132159] [Citation(s) in RCA: 285] [Impact Index Per Article: 25.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Stephen P. Gray
- From the Diabetic Complications Division, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (S.P.G., E.D.M., J.B.d.H., C.K., M.E.C., K.A.J.-D.); the Department of Medicine, Monash University, Monash, Australia (E.D.M., M.E.C., K.A.J.-D.); Epigenetics in Human Health and Disease, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (J.O., A.E.-O.); GenKyoTex SA, Geneva, Switzerland (C.S., F.H.); Ottawa Hospital Research Institute, Ottawa, Canada (A.C.M., R.M.T.); Institute of
| | - Elyse Di Marco
- From the Diabetic Complications Division, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (S.P.G., E.D.M., J.B.d.H., C.K., M.E.C., K.A.J.-D.); the Department of Medicine, Monash University, Monash, Australia (E.D.M., M.E.C., K.A.J.-D.); Epigenetics in Human Health and Disease, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (J.O., A.E.-O.); GenKyoTex SA, Geneva, Switzerland (C.S., F.H.); Ottawa Hospital Research Institute, Ottawa, Canada (A.C.M., R.M.T.); Institute of
| | - Jun Okabe
- From the Diabetic Complications Division, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (S.P.G., E.D.M., J.B.d.H., C.K., M.E.C., K.A.J.-D.); the Department of Medicine, Monash University, Monash, Australia (E.D.M., M.E.C., K.A.J.-D.); Epigenetics in Human Health and Disease, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (J.O., A.E.-O.); GenKyoTex SA, Geneva, Switzerland (C.S., F.H.); Ottawa Hospital Research Institute, Ottawa, Canada (A.C.M., R.M.T.); Institute of
| | - Cedric Szyndralewiez
- From the Diabetic Complications Division, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (S.P.G., E.D.M., J.B.d.H., C.K., M.E.C., K.A.J.-D.); the Department of Medicine, Monash University, Monash, Australia (E.D.M., M.E.C., K.A.J.-D.); Epigenetics in Human Health and Disease, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (J.O., A.E.-O.); GenKyoTex SA, Geneva, Switzerland (C.S., F.H.); Ottawa Hospital Research Institute, Ottawa, Canada (A.C.M., R.M.T.); Institute of
| | - Freddy Heitz
- From the Diabetic Complications Division, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (S.P.G., E.D.M., J.B.d.H., C.K., M.E.C., K.A.J.-D.); the Department of Medicine, Monash University, Monash, Australia (E.D.M., M.E.C., K.A.J.-D.); Epigenetics in Human Health and Disease, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (J.O., A.E.-O.); GenKyoTex SA, Geneva, Switzerland (C.S., F.H.); Ottawa Hospital Research Institute, Ottawa, Canada (A.C.M., R.M.T.); Institute of
| | - Augusto C. Montezano
- From the Diabetic Complications Division, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (S.P.G., E.D.M., J.B.d.H., C.K., M.E.C., K.A.J.-D.); the Department of Medicine, Monash University, Monash, Australia (E.D.M., M.E.C., K.A.J.-D.); Epigenetics in Human Health and Disease, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (J.O., A.E.-O.); GenKyoTex SA, Geneva, Switzerland (C.S., F.H.); Ottawa Hospital Research Institute, Ottawa, Canada (A.C.M., R.M.T.); Institute of
| | - Judy B. de Haan
- From the Diabetic Complications Division, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (S.P.G., E.D.M., J.B.d.H., C.K., M.E.C., K.A.J.-D.); the Department of Medicine, Monash University, Monash, Australia (E.D.M., M.E.C., K.A.J.-D.); Epigenetics in Human Health and Disease, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (J.O., A.E.-O.); GenKyoTex SA, Geneva, Switzerland (C.S., F.H.); Ottawa Hospital Research Institute, Ottawa, Canada (A.C.M., R.M.T.); Institute of
| | - Christine Koulis
- From the Diabetic Complications Division, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (S.P.G., E.D.M., J.B.d.H., C.K., M.E.C., K.A.J.-D.); the Department of Medicine, Monash University, Monash, Australia (E.D.M., M.E.C., K.A.J.-D.); Epigenetics in Human Health and Disease, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (J.O., A.E.-O.); GenKyoTex SA, Geneva, Switzerland (C.S., F.H.); Ottawa Hospital Research Institute, Ottawa, Canada (A.C.M., R.M.T.); Institute of
| | - Assam El-Osta
- From the Diabetic Complications Division, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (S.P.G., E.D.M., J.B.d.H., C.K., M.E.C., K.A.J.-D.); the Department of Medicine, Monash University, Monash, Australia (E.D.M., M.E.C., K.A.J.-D.); Epigenetics in Human Health and Disease, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (J.O., A.E.-O.); GenKyoTex SA, Geneva, Switzerland (C.S., F.H.); Ottawa Hospital Research Institute, Ottawa, Canada (A.C.M., R.M.T.); Institute of
| | - Karen L. Andrews
- From the Diabetic Complications Division, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (S.P.G., E.D.M., J.B.d.H., C.K., M.E.C., K.A.J.-D.); the Department of Medicine, Monash University, Monash, Australia (E.D.M., M.E.C., K.A.J.-D.); Epigenetics in Human Health and Disease, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (J.O., A.E.-O.); GenKyoTex SA, Geneva, Switzerland (C.S., F.H.); Ottawa Hospital Research Institute, Ottawa, Canada (A.C.M., R.M.T.); Institute of
| | - Jaye P. F. Chin-Dusting
- From the Diabetic Complications Division, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (S.P.G., E.D.M., J.B.d.H., C.K., M.E.C., K.A.J.-D.); the Department of Medicine, Monash University, Monash, Australia (E.D.M., M.E.C., K.A.J.-D.); Epigenetics in Human Health and Disease, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (J.O., A.E.-O.); GenKyoTex SA, Geneva, Switzerland (C.S., F.H.); Ottawa Hospital Research Institute, Ottawa, Canada (A.C.M., R.M.T.); Institute of
| | - Rhian M. Touyz
- From the Diabetic Complications Division, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (S.P.G., E.D.M., J.B.d.H., C.K., M.E.C., K.A.J.-D.); the Department of Medicine, Monash University, Monash, Australia (E.D.M., M.E.C., K.A.J.-D.); Epigenetics in Human Health and Disease, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (J.O., A.E.-O.); GenKyoTex SA, Geneva, Switzerland (C.S., F.H.); Ottawa Hospital Research Institute, Ottawa, Canada (A.C.M., R.M.T.); Institute of
| | - Kirstin Wingler
- From the Diabetic Complications Division, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (S.P.G., E.D.M., J.B.d.H., C.K., M.E.C., K.A.J.-D.); the Department of Medicine, Monash University, Monash, Australia (E.D.M., M.E.C., K.A.J.-D.); Epigenetics in Human Health and Disease, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (J.O., A.E.-O.); GenKyoTex SA, Geneva, Switzerland (C.S., F.H.); Ottawa Hospital Research Institute, Ottawa, Canada (A.C.M., R.M.T.); Institute of
| | - Mark E. Cooper
- From the Diabetic Complications Division, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (S.P.G., E.D.M., J.B.d.H., C.K., M.E.C., K.A.J.-D.); the Department of Medicine, Monash University, Monash, Australia (E.D.M., M.E.C., K.A.J.-D.); Epigenetics in Human Health and Disease, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (J.O., A.E.-O.); GenKyoTex SA, Geneva, Switzerland (C.S., F.H.); Ottawa Hospital Research Institute, Ottawa, Canada (A.C.M., R.M.T.); Institute of
| | - Harald H. H. W. Schmidt
- From the Diabetic Complications Division, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (S.P.G., E.D.M., J.B.d.H., C.K., M.E.C., K.A.J.-D.); the Department of Medicine, Monash University, Monash, Australia (E.D.M., M.E.C., K.A.J.-D.); Epigenetics in Human Health and Disease, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (J.O., A.E.-O.); GenKyoTex SA, Geneva, Switzerland (C.S., F.H.); Ottawa Hospital Research Institute, Ottawa, Canada (A.C.M., R.M.T.); Institute of
| | - Karin A Jandeleit-Dahm
- From the Diabetic Complications Division, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (S.P.G., E.D.M., J.B.d.H., C.K., M.E.C., K.A.J.-D.); the Department of Medicine, Monash University, Monash, Australia (E.D.M., M.E.C., K.A.J.-D.); Epigenetics in Human Health and Disease, Baker IDI Heart & Diabetes Institute, Melbourne, Australia (J.O., A.E.-O.); GenKyoTex SA, Geneva, Switzerland (C.S., F.H.); Ottawa Hospital Research Institute, Ottawa, Canada (A.C.M., R.M.T.); Institute of
| |
Collapse
|